GANX (Gain Therapeutics) FFO


GANX Gain Therapeutics Inc GANX
31 GF Score
Price $1.72
! 2 Warning Signs
View Full Analysis

What is Gain Therapeutics FFO?

FFO (Funds from operations) only applies to REITs.

GANX
31GF Score
Gain Therapeutics Inc GANX
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Gain Therapeutics Business Description

Address 4800 Montgomery Lane, Suite 220, Bethesda, MD, USA, 20814
Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.
31GF Score

Get the complete analysis for GANX

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.72
Price